Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial

作者：Panpan Ye, Bu‐Fan Yao, Yang Yang, Xin‐Mei Yang, Qian Li, Linlin Song, Keguang Chen, Haïyan Zhou, Jinyi Shi, Yehui Zhang, Furong Zhao, Zi-Jia Guo, Shansen Xu, Jia Chen, Aik Han Goh, Shunwei Zhu, Yi Zheng, Wei Zhao · 发表于：Clinical Microbiology and Infection · 年份：2024 · DOI：10.1016/j.cmi.2024.09.007 · 被引用次数：7 · 研究领域：Pharmacogenetics and Drug Metabolism、COVID-19 Clinical Research Studies、Drug-Induced Hepatotoxicity and Protection

Objectives Simnotrelvir is a small-molecule highly specific 3C-like protease inhibitor for anti-SARS-CoV-2 and was approved as a combination drug with ritonavir (simnotrelvir/ritonavir) in China. Simnotrelvir is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), and a weak inhibitor of CYP3A. Ritonavir is a substrate and inhibitor of CYP3A and an inhibitor of P-gp. Hence, the drug-drug interaction potential of simnotrelvir/ritonavir should be investigated. Methods This drug-drug interaction study was an open-label, fixed-sequence, two-period phase I clinical trial in Chinese healthy adult subjects, divided into three cohorts, including simnotrelvir/ritonavir co-administrated with a strong CYP3A and P-gp inhibitor (itraconazole) and inducer (rifampicin), and with a specific CYP3A substrate (midazolam). Results The results demonstrated that compared with administration of simnotrelvir/ritonavir alone, the co-administration with itraconazole increased the geometric least-square mean ratio (GMR) of the expose (area under the plasma concentration-time curve from time zero to the lowest detectable plasma concentration [AUC 0-t ]) of simnotrelvir by 25% (GMR 125%, 90% CI 114–137%), whereas co-administration with rifampicin significantly decreased the AUC 0-t of simnotrelvir by 81.5% (GMR 18.5%, 90% CI 16.4–20.9%). Notably, simnotrelvir/ritonavir increased the AUC 0-t of midazolam by 16.69-fold (GMR 1769%, 90% CI 1551–2018%). The co-administration of simnotrelvir/ri...